Biodesix Plans 2026 Revenue of $101 Million to $103 Million, About 115 Sales Reps
Photo: TokenPost
Biodesix expects 2026 revenue of $101 million to $103 million and plans to end the year with about 115 sales representatives, with the range midpoint implying roughly 15% growth over 2025. The company’s outlook incorporates its third-quarter results, the pace of sales-team hiring and training, and the timing of development-services contracts. Third-quarter total revenue rose 10%. Diagnostic testing revenue increased 16%, test volumes grew 24% and gross margin was 81%. Management attributed a shortfall against its plans to having fewer sales representatives than expected, greater seasonality in primary care and delayed development-services projects.
Source: TokenPost
